On May 15, 2025, analyst Jay Olson from Oppenheimer released an update regarding Jasper Therapeutics (JSPR, Financial). Oppenheimer has maintained its 'Outperform' rating for the company. However, the firm has lowered its price target from $80.00 to $65.00 USD per share.
The adjustment represents an 18.75% decrease in the price target for Jasper Therapeutics (JSPR, Financial). Despite the reduction in the price target, Oppenheimer's 'Outperform' rating indicates a positive outlook on the stock's performance relative to the market.
Investors and stakeholders of Jasper Therapeutics (JSPR, Financial) may want to consider these updated figures and analyst insights when making decisions related to the stock. This update from Oppenheimer reflects a recalibration of expectations while maintaining confidence in the company's overall growth potential.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $47.88 with a high estimate of $70.00 and a low estimate of $15.00. The average target implies an upside of 885.45% from the current price of $4.86. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
